Compendium of Cancer Genome Aberrations

Changes

MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray (view source)

Revision as of 16:52, 3 January 2020

2,008 bytes added ,  16:52, 3 January 2020
m
Added reference links
Line 68: Line 68:  
|
 
|
 
|Recurrent
 
|Recurrent
−
|<ref name=":13" /><ref name=":3" /><ref name=":8" /><ref name=":4" /><ref name=":9" /><ref name=":5" /><ref name=":2" /> 92<ref name=":18" />
+
|<ref name=":13" /><ref name=":3" /><ref name=":8" /><ref name=":4" /><ref name=":9" /><ref name=":5" /><ref name=":2" /><ref name=":29">Nowak D, Nolte F, Mossner M, Nowak V, Baldus CD, Hopfer O, et al. Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. Exp Hematol 2009;37:215-24.[https://www.ncbi.nlm.nih.gov/pubmed/19135900]</ref><ref name=":18" />
 
|-
 
|-
 
|
 
|
Line 96: Line 96:  
|''TP53''
 
|''TP53''
 
|Recurrent
 
|Recurrent
−
|<ref name=":3" /><ref name=":9" />34<ref name=":12" /><ref name=":27" />
+
|<ref name=":3" /><ref name=":9" /><ref name=":30">Zhang R, Kim YM, Wang X, Li Y, Lu X, Sternenberger AR, et al. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q). Int J Med Sci 2015;12:719-26.[https://www.ncbi.nlm.nih.gov/pubmed/26392809]</ref><ref name=":12" /><ref name=":27" />
 
|-
 
|-
 
|
 
|
Line 110: Line 110:  
|
 
|
 
|Recurrent
 
|Recurrent
−
|<ref name=":3" /><ref name=":6" />62, 65<ref name=":27" /><ref name=":28" /><ref name=":22" />
+
|<ref name=":3" /><ref name=":6" /><ref name=":31">Vercauteren SM, Sung S, Starczynowski DT, Lam WL, Bruyere H, Horsman DE, et al. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. Am J Clin Pathol 2010;134:119-26. [https://www.ncbi.nlm.nih.gov/pubmed/20551276]</ref><ref name=":32">da Silva FB, Machado-Neto JA, Bertini V, Velloso E, Ratis CA, Calado RT, et al. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. J Clin Pathol 2017;70:435-42. [https://www.ncbi.nlm.nih.gov/pubmed/27836923]</ref><ref name=":27" /><ref name=":28" /><ref name=":22" />
 
|-
 
|-
 
|
 
|
Line 117: Line 117:  
|''RUNX1''
 
|''RUNX1''
 
|Prognostic for progression to AML
 
|Prognostic for progression to AML
−
|<ref name=":3" /><ref name=":23" /><ref name=":24" /><ref name=":12" /><ref name=":6" />92]
+
|<ref name=":3" /><ref name=":23" /><ref name=":24" /><ref name=":12" /><ref name=":6" /><ref name=":29" />
 
|-
 
|-
 
|MDS/MPN
 
|MDS/MPN
Line 124: Line 124:  
|''TET2''
 
|''TET2''
 
|Recurrent
 
|Recurrent
−
|<ref name=":13" />20<ref name=":10" /><ref name=":17" />65]
+
|<ref name=":13" /><ref name=":33">Palomo L, Xicoy B, Garcia O, Mallo M, Adema V, Cabezon M, et al. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. Am J Hematol 2016;91:185-92.[https://www.ncbi.nlm.nih.gov/pubmed/26509444]</ref><ref name=":10" /><ref name=":17" /><ref name=":32" />
 
|-
 
|-
 
|
 
|
Line 131: Line 131:  
|''Likely CUX1''
 
|''Likely CUX1''
 
|Recurrent
 
|Recurrent
−
|<ref name=":13" />20<ref name=":5" /><ref name=":6" /><ref name=":17" />
+
|<ref name=":13" /><ref name=":33" /><ref name=":5" /><ref name=":6" /><ref name=":17" />
 
|-
 
|-
 
|
 
|
Line 138: Line 138:  
|''CBL''
 
|''CBL''
 
|Recurrent
 
|Recurrent
−
|<ref name=":13" />20<ref name=":10" /><ref name=":5" />44]
+
|<ref name=":13" /><ref name=":33" /><ref name=":10" /><ref name=":5" />44]
 
|-
 
|-
 
|MPN
 
|MPN
Line 223: Line 223:  
|3
 
|3
 
|
 
|
−
<ref name=":19" /><ref name=":3" />62]
+
<ref name=":19" /><ref name=":3" /><ref name=":31" />
 
|-
 
|-
 
|1
 
|1
Line 295: Line 295:  
|D, P (Good  when isolated)
 
|D, P (Good  when isolated)
 
|1
 
|1
−
|<ref name=":3" /><ref name=":19" /><ref name=":14" /><ref name=":23" />19<ref name=":8" /><ref name=":0" /><ref name=":9" /><ref name=":20" />34, <ref name=":1" /><ref name=":25" />43<ref name=":16" /><ref name=":2" /> 62<ref name=":21" /><ref name=":17" />65<ref name=":27" /><ref name=":7" /><ref name=":22" />116]
+
|<ref name=":3" /><ref name=":19" /><ref name=":14" /><ref name=":23" />19<ref name=":8" /><ref name=":0" /><ref name=":9" /><ref name=":20" /><ref name=":30" /><ref name=":1" /><ref name=":25" />43<ref name=":16" /><ref name=":2" /><ref name=":31" /><ref name=":21" /><ref name=":17" /><ref name=":32" /><ref name=":27" /><ref name=":7" /><ref name=":22" />116]
 
|-
 
|-
 
|7
 
|7
Line 304: Line 304:  
|D, P  (Intermediate)
 
|D, P  (Intermediate)
 
|1
 
|1
−
|<ref name=":3" /><ref name=":19" /><ref name=":23" />19,<ref name=":0" /><ref name=":9" /><ref name=":24" />34<ref name=":25" /><ref name=":16" /><ref name=":2" /><ref name=":6" /><ref name=":26" /><ref name=":27" /><ref name=":7" /><ref name=":22" />
+
|<ref name=":3" /><ref name=":19" /><ref name=":23" />19,<ref name=":0" /><ref name=":9" /><ref name=":24" /><ref name=":30" /><ref name=":25" /><ref name=":16" /><ref name=":2" /><ref name=":6" /><ref name=":26" /><ref name=":27" /><ref name=":7" /><ref name=":22" />
 
|-
 
|-
 
|7
 
|7
Line 313: Line 313:  
|Recurrent
 
|Recurrent
 
|2
 
|2
−
|<ref name=":13" /><ref name=":3" /><ref name=":14" />19<ref name=":8" /><ref name=":4" /><ref name=":9" /><ref name=":5" /><ref name=":2" />92<ref name=":18" />
+
|<ref name=":13" /><ref name=":3" /><ref name=":14" />19<ref name=":8" /><ref name=":4" /><ref name=":9" /><ref name=":5" /><ref name=":2" /><ref name=":29" /><ref name=":18" />
 
|-
 
|-
 
|7
 
|7
Line 322: Line 322:  
|D, P (Poor)
 
|D, P (Poor)
 
|1
 
|1
−
|[34<ref name=":25" /><ref name=":16" /><ref name=":17" /><ref name=":26" /><ref name=":27" /><ref name=":7" /><ref name=":28" /><ref name=":22" />
+
|<ref name=":30" /><ref name=":25" /><ref name=":16" /><ref name=":17" /><ref name=":26" /><ref name=":27" /><ref name=":7" /><ref name=":28" /><ref name=":22" />
 
|-
 
|-
 
|8
 
|8
Line 331: Line 331:  
|P  (Intermediate)**
 
|P  (Intermediate)**
 
|1
 
|1
−
|<ref name=":3" /><ref name=":8" /><ref name=":9" />34<ref name=":12" /><ref name=":2" /><ref name=":6" /> 62, 74<ref name=":26" /><ref name=":27" /><ref name=":22" />
+
|<ref name=":3" /><ref name=":8" /><ref name=":9" /><ref name=":30" /><ref name=":12" /><ref name=":2" /><ref name=":6" /><ref name=":31" />74<ref name=":26" /><ref name=":27" /><ref name=":22" />
 
|-
 
|-
 
|9
 
|9
Line 358: Line 358:  
|D, P (Very  Good)
 
|D, P (Very  Good)
 
|1
 
|1
−
|<ref name=":3" /> 62]
+
|<ref name=":3" /><ref name=":31" />
 
|-
 
|-
 
|11
 
|11
Line 448: Line 448:  
|Recurrent
 
|Recurrent
 
|3
 
|3
−
|<ref name=":3" />92]
+
|<ref name=":3" /><ref name=":29" />
 
|-
 
|-
 
|17
 
|17
Line 457: Line 457:  
|P (Poor)
 
|P (Poor)
 
|1
 
|1
−
|<ref name=":3" /><ref name=":9" />34, 43<ref name=":12" /><ref name=":2" /><ref name=":27" />
+
|<ref name=":3" /><ref name=":9" /><ref name=":30" />43<ref name=":12" /><ref name=":2" /><ref name=":27" />
 
|-
 
|-
 
|17
 
|17
Line 529: Line 529:  
|P (Good)**
 
|P (Good)**
 
|1
 
|1
−
|<ref name=":3" /><ref name=":8" /><ref name=":0" /> 43,<ref name=":2" /><ref name=":6" />62, 65, 92<ref name=":27" /><ref name=":28" />112<ref name=":19" /> 30, 46, 114, 117]
+
|<ref name=":3" /><ref name=":8" /><ref name=":0" /> 43,<ref name=":2" /><ref name=":6" /><ref name=":31" />65<ref name=":29" /><ref name=":27" /><ref name=":28" />112<ref name=":19" /> 30<ref name=":16" />114, 117]
 
|-
 
|-
 
|20
 
|20
Line 538: Line 538:  
|Recurrent
 
|Recurrent
 
|2
 
|2
−
|<ref name=":2" />92]
+
|<ref name=":2" /><ref name=":29" />
 
|-
 
|-
 
|21
 
|21
Line 547: Line 547:  
|D, P (Poor)
 
|D, P (Poor)
 
|2
 
|2
−
|<ref name=":3" /><ref name=":14" /><ref name=":23" />21<ref name=":24" />34<ref name=":12" />
+
|<ref name=":3" /><ref name=":14" /><ref name=":23" />21<ref name=":24" /><ref name=":30" /><ref name=":12" />
 
|-
 
|-
 
|21
 
|21
Line 612: Line 612:  
|Recurrent
 
|Recurrent
 
|2
 
|2
−
|<ref name=":13" />20<ref name=":10" /><ref name=":5" /><ref name=":17" />65]
+
|<ref name=":13" /><ref name=":33" /><ref name=":10" /><ref name=":5" /><ref name=":17" /><ref name=":32" />
 
|-
 
|-
 
|5
 
|5
Line 639: Line 639:  
|Recurrent
 
|Recurrent
 
|2
 
|2
−
|<ref name=":13" />20<ref name=":5" /><ref name=":6" /><ref name=":17" />
+
|<ref name=":13" /><ref name=":33" /><ref name=":5" /><ref name=":6" /><ref name=":17" />
 
|-
 
|-
 
|8
 
|8
Line 666: Line 666:  
|Recurrent
 
|Recurrent
 
|2
 
|2
−
|<ref name=":13" />20<ref name=":10" /><ref name=":5" />
+
|<ref name=":13" /><ref name=":33" /><ref name=":10" /><ref name=":5" />
 
|-
 
|-
 
|12
 
|12
Line 675: Line 675:  
|P  (Intermediate)
 
|P  (Intermediate)
 
|1
 
|1
−
|[20, 28]
+
|<ref name=":33" />28]
 
|-
 
|-
 
|13
 
|13
Line 720: Line 720:  
|P  (Intermediate)
 
|P  (Intermediate)
 
|2
 
|2
−
|[20<ref name=":10" />
+
|<ref name=":33" /><ref name=":10" />
 
|-
 
|-
 
|21
 
|21
Line 729: Line 729:  
|Recurrent
 
|Recurrent
 
|2
 
|2
−
|[20<ref name=":5" />
+
|<ref name=":33" /><ref name=":5" />
 
|}
 
|}
 
'''Table 4.''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in  
 
'''Table 4.''' A comprehensive list of CNAs and CN-LOH of known or likely clinical significance in  
Pitel.Beth
43

edits

Retrieved from "https://ccga.io/index.php/Special:MobileDiff/6830"